Shares of other companies:
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
AMGN Stock News and Mentions of Amgen Inc. Stocktwits
Updated: April 26, 2024 (09:55)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Amgen Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Amgen Inc. (AMGN).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Amgen stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Amgen Inc. (AMGN)
April 25, 2024 (20:45) / "PR Newswire" (by Inc.)
Mahesh Krishnan Elected to Halozyme's Board of Directors
SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. ( NASDAQ: HALO ) ( "Halozyme" ) today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
In Article Trend: Somewhat-Bullish
April 25, 2024 (17:47) / "Zacks Commentary" (by Zacks Equity Research)
AstraZeneca ( AZN ) Q1 Earnings & Sales Beat Estimates, Stock Up
AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
In Article Trend: Neutral
April 25, 2024 (14:02) / "Zacks Commentary" (by Zacks Equity Research)
Analysts Estimate Amgen ( AMGN ) to Report a Decline in Earnings: What to Look Out for
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 24, 2024 (18:29) / "Benzinga" (by Vandana Singh)
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? - Cullinan Therapeutics ( NASDAQ:CGEM )
A recent academic case study, published on April 22, examined using Amgen Inc's AMGN Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The findings have implications for Cullinan Therapeutics Inc's CGEM CLN-978, a similar CD19xCD3 bispecific T-cell ...
In Article Trend: Somewhat-Bullish
April 24, 2024 (16:05) / "Zacks Commentary" (by Sweta Killa)
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
In Article Trend: Neutral
April 24, 2024 (14:02) / "GlobeNewswire" (by Inc.)
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology ( ASCO ) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( Coherus, Nasdaq: CHRS ) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 ...
In Article Trend: Neutral
April 23, 2024 (13:15) / "Motley Fool" (by George Budwell)
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment?
In Article Trend: Somewhat-Bullish
April 23, 2024 (12:15) / "Motley Fool" (by George Budwell)
1 No-Brainer Vanguard Fund to Buy Right Now
This Vanguard growth fund is home to some of the world's most innovative companies.
In Article Trend: Somewhat-Bullish
April 22, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Amgen ( AMGN ) Outpaced the Stock Market Today
In the most recent trading session, Amgen (AMGN) closed at $271.48, indicating a +0.95% shift from the previous trading day.
In Article Trend: Neutral
April 22, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Neutral
April 19, 2024 (13:45) / "Benzinga" (by Benzinga Insights)
How Is The Market Feeling About Amgen? - Amgen ( NASDAQ:AMGN )
Amgen's AMGN short percent of float has fallen 5.77% since its last report. The company recently reported that it has 10.47 million shares sold short, which is 1.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.83 days to cover their ...
In Article Trend: Somewhat-Bullish
April 18, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.
In Article Trend: Neutral
April 18, 2024 (12:51) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly's ( LLY ) Tirzepatide Meets Goals in Sleep Apnea Studies
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.
In Article Trend: Neutral
April 17, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Suffers a Larger Drop Than the General Market: Key Insights
Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.
In Article Trend: Neutral
April 17, 2024 (18:39) / "Benzinga" (by Vandana Singh)
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick - AstraZeneca ( NASDAQ:AZN ) , Amgen ( NASDAQ:AMGN )
Tuesday, Amgen Inc AMGN provided an update regarding the results of the Phase 2a COURSE trial for Tezspire ( tezepelumab-ekko ) in chronic obstructive pulmonary disease ( COPD ) . Tezspire is a registered trademark of Amgen and AstraZeneca Plc AZN.
In Article Trend: Somewhat-Bullish
April 17, 2024 (12:21) / "Benzinga" (by Avi Kapoor)
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Visa ( NYSE:V )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut the price target for Unity Biotechnology, Inc. UBX from $10 to $8.
In Article Trend: Neutral
April 17, 2024 (11:30) / "Motley Fool" (by George Budwell)
Can This High-Yield Dividend Stock Keep Beating the S&P 500?
Amgen's shares have come under pressure this year, making it a compelling bargain buy.
In Article Trend: Somewhat-Bullish
April 17, 2024 (08:30) / "Motley Fool" (by James Brumley)
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.
In Article Trend: Somewhat-Bullish
April 15, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
April 15, 2024 (13:07) / "Zacks Commentary" (by Zacks Equity Research)
Amgen Inc. ( AMGN ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
April 15, 2024 (12:29) / "Benzinga" (by Avi Kapoor)
Amgen, Shell And More On CNBC's 'Final Trades' - Shell ( NYSE:SHEL ) , Amgen ( NASDAQ:AMGN )
On CNBC's "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust said Shell plc SHEL has 12% free On April 5, Shell updated its first quarter FY24 operational outlook, reflecting lower results from its liquefied natural gas ( LNG ) trading business.
In Article Trend: Somewhat-Bullish
April 12, 2024 (16:31) / "Benzinga" (by Benzinga Insights)
Looking At Amgen's Recent Unusual Options Activity - Amgen ( NASDAQ:AMGN )
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 13 unusual trades. Delving into the details, we found 46% of traders were bullish, while 53% showed bearish tendencies.
In Article Trend: Neutral
April 11, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Laps the Stock Market: Here's Why
In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
April 11, 2024 (12:00) / "Motley Fool" (by David Jagielski)
Is Amgen Stock a Buy?
Amgen's stock isn't expensive, but the business does face some challenges, which could have investors thinking twice.
In Article Trend: Neutral
April 9, 2024 (11:02) / "Zacks Commentary" (by Zacks Equity Research)
Biophytis ( BPTS ) to Begin Phase II Obesity Study, Stock Up
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.
In Article Trend: Somewhat-Bullish
April 9, 2024 (11:00) / "Business Insider" (by Chris MacDonald)
3 High-Growth Biotech Stocks Investors Shouldn't Sleep On in April
It's been a volatile start to the second quarter for many sectors. However, investors continue to seek out undervalued biotech stocks for robust returns over the long term. Plenty of options exist in various niches within the biotech sector.
In Article Trend: Somewhat-Bullish
April 8, 2024 (22:42) / "GlobeNewswire" (by Opthea Limited)
Opthea Appoints John Han, PharmD, as VP Medical Affairs
Brings extensive experience in retinal and ophthalmology diseases Brings extensive experience in retinal and ophthalmology diseases ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
April 8, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting - Coherus BioSciences ( NASDAQ:CHRS )
- In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion - - Mechanism may enhance antitumor responses with immunotherapy - - First novel immuno-oncology ...
In Article Trend: Neutral
April 6, 2024 (12:45) / "Motley Fool" (by Prosper Junior Bakiny)
2 Biotech Stocks to Buy Hand Over Fist in April
These drugmakers have made important moves over the past year.
In Article Trend: Somewhat-Bullish
April 5, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Ascends But Remains Behind Market: Some Facts to Note
Amgen (AMGN) concluded the recent trading session at $269.95, signifying a +0.69% move from its prior day's close.
In Article Trend: Somewhat-Bullish
April 5, 2024 (16:35) / "Investors Business Daily" (by ALLISON GATLIN)
Why A Pullback Is Bullish For IBD Stock Of The Day Novo Nordisk
Novo Nordisk ( NVO ) is Friday's IBD Stock Of The Day. After hitting a record high in March, shares have pulled back amid new developments in the weight-loss drugs frenzy. Last month, Novo said its next-generation weight-loss pill, amycretin, outperformed blockbuster Wegovy in an early-stage ...
In Article Trend: Somewhat-Bullish
April 5, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is iShares Biotechnology ETF ( IBB ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 5, 2024 (08:05) / "Motley Fool" (by James Brumley)
3 Stocks to Consider Adding to Your Retirement Portfolio in April
Use the recent short-term weakness from these powerhouse companies' stocks to your advantage.
In Article Trend: Somewhat-Bullish
April 3, 2024 (15:14) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Amgen ( AMGN ) Stock is Outperforming the Industry
Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to make up for lower revenues from oncology biosimilars and ...
In Article Trend: Somewhat-Bullish
April 2, 2024 (18:15) / "Benzinga" (by Benzinga Insights)
Amgen Unusual Options Activity For April 02 - Amgen ( NASDAQ:AMGN )
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 11 unusual trades. Delving into the details, we found 18% of traders were bullish, while 81% showed bearish tendencies.
In Article Trend: Neutral
April 2, 2024 (14:52) / "Investors Business Daily" (by Investor's Business Daily)
Dow Jones Dives As Calvin Klein Parent Craters; Cathie Wood Loads Up On This Stock Amid 45% Downtrend
Dow Jones Dives As Calvin Klein Parent Craters. Cathie Wood Loads Up On This Stock Amid 45% Downtrend Investor's Business Daily ...
In Article Trend: Neutral
April 1, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Amgen (AMGN) closed the most recent trading day at $283.04, moving -0.45% from the previous trading session.
In Article Trend: Somewhat-Bullish
April 1, 2024 (16:10) / "Zacks Commentary" (by Zacks Equity Research)
Why Amgen ( AMGN ) is Poised to Beat Earnings Estimates Again
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In Article Trend: Somewhat-Bullish
April 1, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
April 1, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Invesco Pharmaceuticals ETF ( PJP ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (08:24) / "PR Newswire"
Enzyme-linked immunosorbent assay (Elisa) testing market size to Increase by USD 564.97 million between 2022 ... - PR Newswire
Enzyme-linked immunosorbent assay ( Elisa ) testing market size to Increase by USD 564.97 million between 2022 ... PR ...
In Article Trend: Somewhat-Bullish
March 29, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Amgen Inc. ( AMGN ) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
March 29, 2024 (08:50) / "Stocknews.com" (by Defense World Staff)
Amgen ( NASDAQ:AMGN ) Downgraded by StockNews.com to Hold
StockNews.com lowered shares of Amgen ( NASDAQ:AMGN - Free Report ) from a buy rating to a hold rating in a research report report published on Thursday. Several other equities analysts have also weighed in on the stock.
In Article Trend: Somewhat-Bullish
March 28, 2024 (18:28) / "Benzinga" (by Vandana Singh)
Amgen's Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst Says - Amgen ( NASDAQ:AMGN )
Raymond James has resumed coverage of Amgen Inc AMGN, noting a diversified portfolio where Amgen has a strong presence that can help drive solid, sustainable long-term growth.
In Article Trend: Somewhat-Bullish
March 28, 2024 (16:03) / "Benzinga" (by Benzinga Insights)
Amgen Options Trading: A Deep Dive into Market Sentiment - Amgen ( NASDAQ:AMGN )
Deep-pocketed investors have adopted a bullish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
In Article Trend: Bullish
March 28, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the iShares Biotechnology ETF ( IBB ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (12:10) / "Zacks Commentary" (by Zacks Equity Research)
Precision BioSciences ( DTIL ) Reports Q4 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -211.67% and 75.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 26, 2024 (14:21) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Awaits Consumer Confidence Data
U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility. The AI-driven rally of the last 15 months is showing no sign of losing pace.
In Article Trend: Neutral
March 26, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should Schwab U.S. Dividend Equity ETF ( SCHD ) Be on Your Investing Radar?
Style Box ETF report for ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (06:33) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Set to Post Fifth Winning Month Amid Volatility
Wall Street is likely to record the fifth consecutive winning month despite volatility.
In Article Trend: Neutral
March 25, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Amgen (AMGN) closed at $280.82, indicating a +1.68% shift from the previous trading day.
In Article Trend: Neutral
March 25, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
March 22, 2024 (16:18) / "PR Newswire"
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 21, 2024 (11:00) / "Motley Fool" (by Prosper Junior Bakiny)
March 20, 2024 (20:15) / "GlobeNewswire" (by Alvotech)
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a summary of recent pipeline and corporate highlights.
In Article Trend: Neutral
March 20, 2024 (20:15) / "GlobeNewswire" (by Alvotech)
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
REYKJAVIK, Iceland, March 20, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a ...
In Article Trend: Neutral
March 20, 2024 (17:07) / "Investors Business Daily" (by Investor's Business Daily)
Is Pfizer Stock, At A Nine-Year Low, A Sell Amid The Search For Its Big Break?
Pfizer ( PFE ) stock is trading at its lowest point in nine years as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech ( BNTX ) . This month, the European Commission approved Pfizer's Prevnar 20, a vaccine to help protect babies and ...
In Article Trend: Neutral
March 20, 2024 (15:08) / "Investors Business Daily" (by VIDYA RAMAKRISHNAN)
Stocks Rise Ahead Of Fed's Guidance On Rate Cuts; Nvidia, Super Micro Fall
Stock Market Today: Stocks Rise Ahead Of Fed Powell. Nvidia, SMCI Fall As Cisco Rival Breaks Out Investor's Business Daily ...
In Article Trend: Neutral
March 19, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Ascends But Remains Behind Market: Some Facts to Note
In the closing of the recent trading day, Amgen (AMGN) stood at $271.73, denoting a +0.31% change from the preceding trading day.
In Article Trend: Somewhat-Bullish
March 19, 2024 (06:22) / "Stocknews.com" (by Defense World Staff)
Amgen ( NASDAQ:AMGN ) Downgraded by StockNews.com to "Hold"
Amgen ( NASDAQ:AMGN - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Tuesday.
In Article Trend: Somewhat-Bullish
March 18, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Why Amgen ( AMGN ) Outpaced the Stock Market Today
In the latest trading session, Amgen (AMGN) closed at $270.90, marking a +0.76% move from the previous day.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Investors Heavily Search Amgen Inc. ( AMGN ) : Here is What You Need to Know
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
March 18, 2024 (09:36) / "PR Newswire"
Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire
Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... PR ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:30) / "PR Newswire" (by MarketsandMarkets)
Monoclonal Antibody ( mABs ) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...
In Article Trend: Somewhat-Bullish
March 14, 2024 (20:30) / "Benzinga" (by Benzinga Insights)
Looking At Amgen's Recent Unusual Options Activity - Amgen ( NASDAQ:AMGN )
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 11 unusual trades. Delving into the details, we found 36% of traders were bullish, while 63% showed bearish tendencies.
In Article Trend: Neutral
March 13, 2024 (12:24) / "Benzinga" (by Avi Kapoor)
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields - Medtronic ( NYSE:MDT ) , Amgen ( NASDAQ:AMGN )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
In Article Trend: Neutral
March 13, 2024 (01:12) / "Stocknews.com" (by ABMN Staff)
Amgen ( NASDAQ:AMGN ) Upgraded by StockNews.com to "Buy"
StockNews.com upgraded shares of Amgen ( NASDAQ:AMGN - Free Report ) from a hold rating to a buy rating in a report published on Monday.
In Article Trend: Somewhat-Bullish
March 12, 2024 (12:00) / "GlobeNewswire" (by Veru Inc.)
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
MIAMI, March 12, 2024 ( GLOBE NEWSWIRE ) -- Veru Inc. ( NASDAQ: VERU ) , a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome ( ARDS ) , today ...
In Article Trend: Neutral
March 12, 2024 (08:38) / "Stocknews.com" (by Defense World Staff)
Amgen ( NASDAQ:AMGN ) Raised to "Buy" at StockNews.com
StockNews.com upgraded shares of Amgen ( NASDAQ:AMGN - Free Report ) from a hold rating to a buy rating in a research note released on Monday.
In Article Trend: Somewhat-Bullish
March 11, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Why the Market Dipped But Amgen ( AMGN ) Gained Today
In the closing of the recent trading day, Amgen (AMGN) stood at $275.36, denoting a +0.59% change from the preceding trading day.
In Article Trend: Neutral
March 11, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
In Article Trend: Somewhat-Bullish
March 9, 2024 (14:00) / "Motley Fool" (by Motley Fool Staff)
The AI Race Gets Litigious
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
In Article Trend: Neutral
March 8, 2024 (22:48) / "PR Newswire"
Protein Expression Market size to grow by USD 2.45 billion from 2023 to 2027, North America accounts for 37% of ... - PR Newswire
Protein Expression Market size to grow by USD 2.45 billion from 2023 to 2027, North America accounts for 37% of ... PR ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (15:03) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk ( NVO ) Up on Upbeat Data From New Obesity Pill Study
Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
In Article Trend: Somewhat-Bullish
March 8, 2024 (11:47) / "Zacks Commentary" (by Zacks Equity Research)
Viking ( VKTX ) Stock Down on Novo Nordisk's Obesity Pill Data
Viking Therapeutics (VKTX) falls as VK2735's placebo-adjusted mean weight loss after 13 weeks of treatment in a phase II study appears similar to Novo Nordisk's amycretin in a phase I study.
In Article Trend: Neutral
March 7, 2024 (16:31) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Down 6.5% Since Last Earnings Report: Can It Rebound?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 6, 2024 (16:30) / "Benzinga" (by Benzinga Insights)
( AMGN ) - Analyzing Amgen's Short Interest - Amgen ( NASDAQ:AMGN )
Amgen's AMGN short percent of float has risen 18.97% since its last report. The company recently reported that it has 11.09 million shares sold short, which is 2.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.7 days to cover their ...
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Here is What to Know Beyond Why Amgen Inc. ( AMGN ) is a Trending Stock
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
March 6, 2024 (12:45) / "Motley Fool" (by James Brumley)
Is It Time to Buy February's 3 Worst-Performing Dow Jones Stocks?
It's only a bargain price if it's actually worth owning.
In Article Trend: Neutral
March 5, 2024 (18:24) / "Benzinga" (by Globe Newswire)
Sandoz receives FDA approval for first and only denosumab biosimilars - Sandoz Group ( OTC:SDZNY )
Wyost® ( denosumab-bddz ) and Jubbonti® ( denosumab-bddz ) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* ( denosumab ) and Prolia®* ( denosumab )
In Article Trend: Somewhat-Bearish
March 5, 2024 (18:24) / "GlobeNewswire" (by Sandoz International GmbH)
Sandoz receives FDA approval for first and only denosumab biosimilars
MEDIA RELEASE ...
In Article Trend: Neutral
March 4, 2024 (22:50) / "Zacks Commentary" (by Zacks Equity Research)
Amgen ( AMGN ) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Amgen (AMGN) stood at $279.35, denoting a -0.35% change from the preceding trading day.
In Article Trend: Somewhat-Bullish
March 4, 2024 (14:10) / "Zacks Commentary" (by Zacks Equity Research)
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
March 2, 2024 (11:56) / "Motley Fool" (by Alex Carchidi)
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
The biotech tantalized investors with a very promising data update.
In Article Trend: Neutral
March 1, 2024 (16:35) / "Investors Business Daily" (by ALLISON GATLIN)
Lilly Stock Could Join The 1,000 Club With $81 Billion In Obesity Sales
Eli Lilly Stock And The Road To 1,000: The $81 Billion Weight-Loss Drugs Space Investor's Business Daily ...
In Article Trend: Neutral
March 1, 2024 (15:39) / "Benzinga" (by Chris Katje)
Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List Post-iPhone 15, Vision Pro Launches - Apple ( NASDAQ:AAPL ) , Amgen ( NASDAQ:AMGN )
A leading financial analyst company has removed technology giant Apple Inc AAPL from its "Conviction List" one month after first-quarter earnings were reported. What Happened: Apple has had several eventful months with the release of the iPhone 15 in September and the Vision Pro mixed reality ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (12:31) / "Motley Fool" (by Prosper Junior Bakiny)
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks.
In Article Trend: Somewhat-Bullish
February 29, 2024 (23:46) / "MarketWatch" (by Christine Idzelis)
This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag
This week's ETF Wrap digs into the jump in biotech funds, as well as an "unusual" trend in U.S. small-cap stocks versus small-cap tech equities.
In Article Trend: Somewhat-Bullish
February 29, 2024 (14:45) / "Motley Fool" (by George Budwell)
Better Dividend Growth Stock: AbbVie or Amgen?
A strong case can be made for owning both of these dividend growth stocks. But one of them is the better buy.
In Article Trend: Bullish
February 29, 2024 (14:15) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights NVIDIA, Visa, Amgen, Chubb and PACCAR
NVIDIA, Visa, Amgen, Chubb and PACCAR are part of the Zacks top Analyst Blog.
In Article Trend: Somewhat-Bullish
February 28, 2024 (18:42) / "Zacks Commentary" (by Mark Vickery)
Top Research Reports for NVIDIA, Visa & Amgen
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Visa Inc. (V) and Amgen Inc. (AMGN).
In Article Trend: Somewhat-Bullish
February 27, 2024 (16:52) / "Zacks Commentary" (by Zacks Equity Research)
CytomX ( CTMX ) to Report Q4 Earnings: Here's What to Expect
Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.
In Article Trend: Neutral
February 27, 2024 (14:10) / "Zacks Commentary" (by Zacks Equity Research)
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
In Article Trend: Somewhat-Bullish
February 26, 2024 (18:25) / "Benzinga" (by Vandana Singh)
Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs - Amgen ( NASDAQ:AMGN )
Amgen Inc AMGN is expected to unveil updates on various programs this year, targeting significant markets. Despite concerns about the company's long-term growth amid exclusivity losses, Goldman Sachs notes that Amgen ( Buy rating, $350 price target ) is seen as well-positioned to capitalize on ...
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website